Edmond DE Rothschild Holding S.A. Purchases 339,756 Shares of Illumina, Inc. $ILMN

Key Points

• Edmond DE Rothschild Holding S.A. significantly increased its stake in Illumina, Inc. by 133.1% during the 1st quarter, now owning a total of 594,942 shares valued at approximately $47.2 million.
• Illumina's quarterly earnings reported a net margin of 29.36% and $1.19 earnings per share, exceeding consensus estimates, despite a revenue decline of 4.8% year-over-year.
• Wall Street analysts currently hold an average rating of "Hold" for Illumina, with price targets ranging from $85.00 to $128.00 across various research firms.

Edmond DE Rothschild Holding S.A. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 133.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 594,942 shares of the life sciences company's stock after buying an additional 339,756 shares during the period. Illumina comprises about 0.8% of Edmond DE Rothschild Holding S.A.'s holdings, making the stock its 28th largest position. Edmond DE Rothschild Holding S.A. owned approximately 0.38% of Illumina worth $47,203,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ILMN. Benjamin Edwards Inc. bought a new stake in shares of Illumina during the 4th quarter valued at $541,000. Captrust Financial Advisors raised its position in Illumina by 17.2% during the 4th quarter. Captrust Financial Advisors now owns 10,049 shares of the life sciences company's stock valued at $1,343,000 after purchasing an additional 1,473 shares during the last quarter. Bridgefront Capital LLC bought a new position in shares of Illumina in the 4th quarter worth approximately $256,000. Brevan Howard Capital Management LP raised its position in shares of Illumina by 18.3% in the 4th quarter. Brevan Howard Capital Management LP now owns 11,263 shares of the life sciences company's stock worth $1,505,000 after acquiring an additional 1,743 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Illumina by 16.9% during the 4th quarter. Cetera Investment Advisers now owns 23,107 shares of the life sciences company's stock valued at $3,088,000 after purchasing an additional 3,345 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of ILMN stock traded down $0.05 during trading hours on Tuesday, reaching $98.14. The stock had a trading volume of 392,303 shares, compared to its average volume of 2,264,903. The firm has a market capitalization of $15.08 billion, a PE ratio of 12.43, a price-to-earnings-growth ratio of 2.22 and a beta of 1.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a 50-day simple moving average of $99.68 and a 200-day simple moving average of $88.42. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's quarterly revenue was down 4.8% compared to the same quarter last year. During the same period last year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the topic of a number of research reports. Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research note on Friday, July 11th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research note on Friday, August 1st. Daiwa America downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research note on Tuesday, September 2nd. Finally, Evercore ISI increased their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $123.06.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.